Skip to main content
Premium Trial:

Request an Annual Quote

Another Drug to Cross Off the Personalized Med List

A feature article in the August issue of Scientific American throws into question the concept of race-based drugs — how race is, or is not, meaningfully taken into account as a way to label genetic variation among individuals in clinical trials. Author Jonathan Kahn details the history of the making of BiDil, a drug intended to treat congestive heart failure only in African-Americans, into the first "ethnic drug." Kahn writes that the drug was FDA-approved under faulty evidence, and warns that most scientists don't see race as a useful way to predict drug response or genetic variation when it comes to creating more drugs like BiDil.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.